Once these most recent quarterly results are finalized, they will be run through TheStreet.com Ratings' model and our ratings will be adjusted accordingly. To keep up to date on all of our ratings, visit TheStreet.com Ratings Screener.
On February 26, 2009, software company
reported that its Q4 FY08 earnings rose 9.0%, on higher revenue. Net income increased to $31.91 million from $29.29 million. On a per share basis, earnings fell to $0.34 per share from $0.36 per share in Q4 FY07, due to higher share count. On a non-GAAP basis, net income was $46.56 million or $0.50 per share, beating the most recent consensus estimate of $0.44 per share.
Revenue grew 21.6% to $135.30 million from $111.24 million a year ago. Software licenses revenue improved 19.6% to $90.38 million from $75.56 million, while maintenance and services revenue rose 25.9% to $44.92 million from $35.67 million.
Recently, the company announced its participation in the Osteoporotic Virtual Physiological Human Project (VPHOP), launched by a European consortium. The project aims to develop a new generation of medical technologies designed to predict the patient-specific risk of osteoporosis and bone fracture.
During FY08, Ansys' net income grew 35.5% to $111.67 million or $1.29 per share from $82.39 million or $1.02 per share in FY07. Adjusted net income was $152.41 million or $1.76 per share, up 39.8% from $109.00 million or $1.34 per share. Full year GAAP revenue advanced 24.1 to $478.34 million from $385.34 million, while non-GAAP revenue grew 27.3% to $492.96 million from $387.17 million last year.
Looking ahead to Q1 FY09, Ansys expects its GAAP earnings to be in the range of $0.17 per share to $0.25 per share and non-GAAP earnings of $0.33 per share to $0.39 per share. The company forecast revenue in the range of $117.00 million to $125.00 million. For FY09, the company anticipates earnings of $1.01 to $1.36 per share on expected sales of $522 million.